The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

accounts for 1.7% of all cancer-related deaths. Neuroendocrine carcinoma of the gallbladder (GB-NEC) is a rare subtype of GBC that is more malignant than GBC. Small-cell neuroendocrine carcinoma of ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine ... activator PAC-1 enhances PNET cell death in cell ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced ...

for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this patient group, according to a press release from the Dana-Farber Cancer Institute.

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). The approval is supported by data from the phase 3 CABINET trial.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX ® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... Cancer Network updated its guidelines to recommend Cabometyx as a category 1 ...